Cargando…

Development and validation of a chemotherapy tolerance prediction model for Chinese multiple myeloma patients: The TM frailty score

OBJECTIVE: The physical fitness of older individuals is heterogeneous, making it difficult to know their chemotherapy tolerance. The toxicities may offset the benefits of anti-myeloma therapy in frail patients. The accurate evaluation of frailty status before chemotherapy is essential. We aimed to e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yadong, Gu, Jingli, Huang, Beihui, Liu, Junru, Li, Xiaozhe, Li, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895409/ https://www.ncbi.nlm.nih.gov/pubmed/36741003 http://dx.doi.org/10.3389/fonc.2023.1103687

Ejemplares similares

Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
por: Sun, Qian, et al.
Publicado: (2022)

Health‐related quality of life of patients with multiple myeloma: A real‐world study in China
por: Li, Xiaozhe, et al.
Publicado: (2020)

P896: DEVELOPMENT AND VALIDATION OF A FRAILTY PREDICTION MODEL MORE SUITABLE FOR MULTIPLE MYELOMA IN CHINESE PATIENTS: THE TM FRAILTY SCORE.
por: Chen, Y., et al.
Publicado: (2022)

Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study
por: Xiaozhe, Li, et al.
Publicado: (2022)

Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
por: Gu, Jingli, et al.
Publicado: (2021)

Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing
por: Zhang, Bingqing, et al.
Publicado: (2019)

Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance
por: Liu, Junru, et al.
Publicado: (2023)

RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells
por: Huang, Beihui, et al.
Publicado: (2023)

1q21 Gain Combined with High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China
por: Li, Xiaozhe, et al.
Publicado: (2019)

Comparison of efficacy, safety, patients’ quality of life, and doctors’ occupational stress between lenalidomide‐based and bortezomib‐based induction in patients with newly diagnosed multiple myeloma
por: Xu, Limei, et al.
Publicado: (2021)

Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma
por: Li, Ying, et al.
Publicado: (2016)

Investigation of the optimal duration of bed rest in the supine position to reduce complications after lumbar puncture combined with intrathecal chemotherapy: a multicenter prospective randomized controlled trial
por: Li, Juan, et al.
Publicado: (2018)

Prediction of cardiovascular adverse events in newly diagnosed multiple myeloma: Development and validation of a risk score prognostic model
por: Yuan, Shuai, et al.
Publicado: (2023)

Clinical and genomic characterization of Chinese patients with functional high-risk multiple myeloma: A real-world validation study
por: Wang, Yu-tong, et al.
Publicado: (2023)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Flow cytometry-based immunophenotypic analysis of primary systemic light chain amyloidosis
por: Diao, Xiangwen, et al.
Publicado: (2017)

Chemotherapy May Obviate Prophylactic Femoral Nail Surgery for Multiple Myeloma Patients With High Mirels’ Score Lesions and Impending Pathological Hip Fracture
por: Divekar, Omkaar, et al.
Publicado: (2023)

Development and Validation of a 9-Gene Prognostic Signature in Patients With Multiple Myeloma
por: Liu, Xiao-Ping, et al.
Publicado: (2019)

What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
por: Gao, Wen, et al.
Publicado: (2020)

Hp-Positive Chinese Patients Should Undergo Colonoscopy Earlier and More Frequently: The Result of a Cross-Sectional Study Based on 13,037 Cases of Gastrointestinal Endoscopy
por: Wang, Cheng, et al.
Publicado: (2021)

Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities
por: Jia, Shuangshuang, et al.
Publicado: (2022)

Symptoms and experiences of frailty in lung cancer patients with chemotherapy: A mixed-method approach
por: Duan, Liran, et al.
Publicado: (2022)

Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles
por: Borisov, Nicolas, et al.
Publicado: (2021)

Remarkable Response to Methylprednisolone in a Multiple Myeloma Patient with Nodal Disease Refractory to High-Dose Chemotherapy
por: Celotto, Kimberly, et al.
Publicado: (2015)

Development and Validation of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data
por: Princic, Nicole, et al.
Publicado: (2016)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Chemotherapy-induced toxic epidermal necrolysis in a patient with multiple myeloma, a case report and literature review
por: X, Rui, et al.
Publicado: (2023)

Development and Validation of a Radiomics Model Based on (18)F-FDG PET of Primary Gastric Cancer for Predicting Peritoneal Metastasis
por: Xue, Beihui, et al.
Publicado: (2021)

Validating the agreement between the geriatric trauma frailty index and four published frailty scores in the Chinese geriatric trauma population
por: Zhao, Fangjie, et al.
Publicado: (2022)

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2020)

Development and validation of a novel fibroblast scoring model for lung adenocarcinoma
por: Wei, Shiyou, et al.
Publicado: (2022)

Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma
por: Guo, Mengjie, et al.
Publicado: (2019)

Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2021)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?
por: Möller, Mandy-Deborah, et al.
Publicado: (2021)

Matrix metalloproteinases and tissue inhibitors in multiple myeloma: promote or inhibit?
por: Li, Yan-Ying, et al.
Publicado: (2023)

Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma
por: Zhuang, Yan, et al.
Publicado: (2023)

Acupuncture Synergized With Bortezomib Improves Survival of Multiple Myeloma Mice via Decreasing Metabolic Ornithine
por: Ke, Mengying, et al.
Publicado: (2021)

Socioeconomic status-based survival disparities and nomogram prediction for patients with multiple myeloma: Results from American and Chinese populations
por: Xu, Jiaxuan, et al.
Publicado: (2022)

Cross-Sectional and Longitudinal Associations Between the Serum G\lobulin Level, and Renal Impairment and All-Cause Deaths in Chinese Patients With Newly Diagnosed Multiple Myeloma
por: Cheng, Jun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rhls6n6po7tbp0fk12i9v1ekrf